BACTEC MGIT 960 PZA KIT

• K Number: K021582
• Device Name: BACTEC MGIT 960 PZA KIT
• Manufacturer: BECTON, DICKINSON & CO.
• Date Cleared: 2002-07-13 ( 60 days)
• Product Code: MJA
• Regulation Number: 866.1640

Intended Use

The BACTEC® MGIT™ 960 PZA Kit is used as a rapid qualitative procedure for susceptibility testing of Mycobacterium tuberculosis, from culture, to pyrazinamide (PZA). The BACTEC® MGIT™ 960 PZA kit is used with the BACTEC® MGIT™ 960 System.

Device Description

The BACTEC® MGIT™ 960 PZA susceptibility test kit is used with the BACTEC® MGIT™ PZA Medium and performed on the BACTEC® MGIT™ 960 System. The PZA Medium tube is supplemented with BACTEC® MGIT™ 960 PZA Supplement and prepared with the appropriate dilution of pyrazinamide as the mechanism for performing the susceptibility test. The BACTEC® MGIT™ 960 PZA susceptibility test utilizes a four to twenty-one day testing protocol. A standardized suspension of Mycobacterium tuberculosis growth is prepared from either solid or liquid culture media. An appropriate dilution is made of this suspension and 0.5 mL is inoculated into a Growth Control tube (drug-free) and a tube containing pyrazinamide (both tubes are referred to as an AST Set). The test interpretation is based on growth of the Mycobacterium tuberculosis isolate in the Growth Control tube compared to the growth in the drug-containing tube. At the completion of the PZA susceptibility testing protocol. the instrument reports a susceptible or resistant result for the Mycobacterium tuberculosis isolate being tested.

Predicate Devices

K895362

Reference Devices

Not Found

AI/ML (Artificial Intelligence / Machine Learning)

No
The description focuses on a chemical susceptibility test and an automated system for monitoring growth, with no mention of AI/ML algorithms for interpretation or analysis.

Therapeutic

No.
The device is used for in-vitro susceptibility testing of Mycobacterium tuberculosis to pyrazinamide, which is a diagnostic purpose, not a therapeutic one.

Diagnostic

Yes

The device is used for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide, which helps determine the appropriate treatment for an infection, thereby aiding in diagnosis and management.

SaMD (Software as a Medical Device)

No

The device description clearly outlines a physical kit with reagents (PZA Medium, PZA Supplement) and a testing protocol involving inoculation of tubes and use with the BACTEC® MGIT™ 960 System, which is a hardware instrument. This is not a software-only device.

IVD (In Vitro Diagnostic)

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

• Intended Use: The intended use clearly states it's a "rapid qualitative procedure for susceptibility testing of Mycobacterium tuberculosis, from culture, to pyrazinamide (PZA)." This involves testing a sample (Mycobacterium tuberculosis from culture) outside of the body to provide information about its susceptibility to a drug.
• Device Description: The description details the use of reagents (PZA Medium, PZA Supplement, pyrazinamide) and a system (BACTEC® MGIT™ 960 System) to perform a test on a biological sample (Mycobacterium tuberculosis growth). The test measures growth in the presence and absence of a drug to determine susceptibility.
• Performance Studies: The document includes analytical and clinical studies evaluating the performance of the test, which is typical for IVD devices. These studies assess reproducibility and agreement with a reference method.
• Predicate Device: The mention of a predicate device (BACTEC® 460TB PZA Kit) which is also an IVD, further supports the classification of this device as an IVD.

In summary, the BACTEC® MGIT™ 960 PZA Kit is designed to perform a test on a biological sample in vitro (outside the body) to provide diagnostic information about the susceptibility of Mycobacterium tuberculosis to pyrazinamide. This aligns directly with the definition of an In Vitro Diagnostic device.

PCCP (Predetermined Change Control Plan) Authorized

N/A

Overview

Intended Use / Indications for Use

The BACTEC® MGIT™ 960 PZA Kit is used as a rapid qualitative procedure for susceptibility testing of Mycobacterium tuberculosis, from culture, to pyrazinamide (PZA). The BACTEC® MGIT™ 960 PZA kit is used with the BACTEC® MGIT™ 960 System.

Product codes

MJA

Device Description

The BACTEC® MGIT™ 960 PZA susceptibility test kit is used with the BACTEC® MGIT™ PZA Medium and performed on the BACTEC® MGIT™ 960 System. The PZA Medium tube is supplemented with BACTEC® MGIT™ 960 PZA Supplement and prepared with the appropriate dilution of pyrazinamide as the mechanism for performing the susceptibility test.

The BACTEC® MGIT™ 960 PZA susceptibility test utilizes a four to twenty-one day testing protocol. A standardized suspension of Mycobacterium tuberculosis growth is prepared from either solid or liquid culture media. An appropriate dilution is made of this suspension and 0.5 mL is inoculated into a Growth Control tube (drug-free) and a tube containing pyrazinamide (both tubes are referred to as an AST Set). The test interpretation is based on growth of the Mycobacterium tuberculosis isolate in the Growth Control tube compared to the growth in the drug-containing tube.

At the completion of the PZA susceptibility testing protocol. the instrument reports a susceptible or resistant result for the Mycobacterium tuberculosis isolate being tested.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Analytical Studies:

Reproducibility Testing

Reproducibility of the BACTEC® MGIT™ 960 PZA susceptibility test was evaluated using twenty-six qualified Mycobacterium tuberculosis strains (including three ATCC® strains). Three different lots of the reagents required to conduct the BACTEC® MGIT™ 960 PZA susceptibility test were evaluated. Observed results were compared to the expected results. The overall reproducibility was 96.8%.

CDC Challenge Panel Testing

The performance of the BACTEC® MGIT™ 960 PZA susceptibility test was evaluated using a panel of challenge strains obtained from the Centers for Disease Control and Prevention (CDC). Observed results were compared to the CDC expected results. The percent agreement was 98.7% to the CDC expected results.

Clinical Studies:

The BACTEC® MGIT™ 960 PZA susceptibility test was evaluated at four geographically diverse clinical sites, composed of regional reference centers and university-based laboratories.

Reproducibility Testing

The reproducibility of the BACTEC® MGIT™ 960 PZA Kit was evaluated at the clinical sites using a panel of five qualified strains. Observed results were compared to expected results. Overall reproducibility was 94%, with a range across sites of 86-100%.

CDC Challenge Panel Testing

The performance of the BACTEC® MGIT™ 960 PZA Kit was evaluated using a panel of challenge strains obtained from the Centers for Disease Control and Prevention (CDC). Observed results were compared to the CDC expected results. The percent agreement was 91.7% to the CDC expected results.

Clinical Isolate Testing

A total of 118 clinical strains of Mycobacterium tuberculosis were evaluated with the BACTEC® MGIT™ 960 PZA susceptibility test and the BACTEC® 460TB PZA test (reference method). This testing included fresh clinical and subculture isolates from both liquid and solid source cultures. A total of 228 PZA test results were generated and analyzed.

Category agreement was calculated for the isolates tested from both liquid and solid source cultures. The BACTEC® MGIT™ 960 PZA susceptibility test demonstrated a category agreement for liguid source culture of 98.2% and a category agreement of 95.6% for solid source culture.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Overall reproducibility was 96.8%.
The percent agreement was 98.7% to the CDC expected results.
Overall reproducibility was 94%, with a range across sites of 86-100%.
The percent agreement was 91.7% to the CDC expected results.
The BACTEC® MGIT™ 960 PZA susceptibility test demonstrated a category agreement for liguid source culture of 98.2% and a category agreement of 95.6% for solid source culture.

Predicate Device(s)

BACTEC® 460TB PZA Kit, K895362

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

Regulation Number and Section

§ 866.1640 Antimicrobial susceptibility test powder.

(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).

Summary

0

KO21582

JUL 1 3 2002

510(k) SUMMARY

| SUBMITTED BY: | Becton Dickinson and Company
7 Loveton Circle
Sparks, MD 21152
Phone: [phone]
Fax: [phone] |
|------------------------|------------------------------------------------------------------------------------------------------------------|
| CONTACT NAME: | Michelle Bandy, Regulatory Affairs Specialist |
| DATE PREPARED: | May 9, 2002 |
| DEVICE TRADE NAME: | BACTEC® MGIT™ 960 PZA Kit |
| DEVICE COMMON NAME: | Antimicrobial susceptibility test powder |
| DEVICE CLASSIFICATION: | 21 CFR§866.1640 |
| PREDICATE DEVICE: | BACTEC® 460TB PZA Kit |

INTENDED USE:

The BACTEC® MGIT™ 960 PZA Kit is used as a rapid qualitative procedure for susceptibility testing of Mycobacterium tuberculosis, from culture, to pyrazinamide (PZA). The BACTEC® MGIT™ 960 PZA kit is used with the BACTEC® MGIT™ 960 System.

DEVICE DESCRIPTION:

The BACTEC® MGIT™ 960 PZA susceptibility test kit is used with the BACTEC® MGIT™ PZA Medium and performed on the BACTEC® MGIT™ 960 System. The PZA Medium tube is supplemented with BACTEC® MGIT™ 960 PZA Supplement and prepared with the appropriate dilution of pyrazinamide as the mechanism for performing the susceptibility test.

The BACTEC® MGIT™ 960 PZA susceptibility test utilizes a four to twenty-one day testing protocol. A standardized suspension of Mycobacterium tuberculosis growth is prepared from either solid or liquid culture media. An appropriate dilution is made of this suspension and 0.5 mL is inoculated into a Growth Control tube (drug-free) and a tube containing pyrazinamide (both tubes are referred to as an AST Set). The test interpretation is based on growth of the Mycobacterium tuberculosis isolate in the Growth Control tube compared to the growth in the drug-containing tube.

At the completion of the PZA susceptibility testing protocol. the instrument reports a susceptible or resistant result for the Mycobacterium tuberculosis isolate being tested.

1

DEVICE COMPARISON:

The BACTEC® MGIT™ 960 PZA susceptibility test is similar to the BACTEC® 460TB PZA susceptibility test in that:

• Both methods test drug susceptibility of Mycobacterium tuberculosis culture . isolates.
• Both methods use the antimycobacterial drug pyrazinamide. .
• Both methods compare organism growth in drug-free medium to organism . growth in medium that contains the drug to obtain a susceptibility result.
• . Both methods provide susceptibility results - susceptible (S) or resistant (R).
• . Both methods utilize a four to twenty-one day protocol.
• Both methods test PZA using a drug concentration of 100 ug/mL. .
• Both methods use Modified Middlebrook 7H9 Broth with a reduced pH. ●
• Both methods may use Mvcobacterium tuberculosis isolates recovered from . either solid or liquid source cultures.

The BACTEC® MGIT™ 960 PZA susceptibility test differs from the BACTEC® 460TB PZA susceptibility test method in that:

• The BACTEC® MGIT™ 960 PZA susceptibility test does not require user . manipulation of the PZA test vials once entered into the instrument while the BACTEC® 460TB PZA susceptibility test requires off-line incubation and a daily manipulation of the PZA test bottles into the instrument for monitoring.
• The BACTEC® MGIT™ 960 PZA susceptibility test is continually monitored by . the instrument while the BACTEC® 460TB PZA susceptibility test is monitored once daily.
• The BACTEC® MGIT™ 960 PZA susceptibility test uses an oxygen sensitive . fluorescent sensor to monitor organism growth while the BACTEC® 460TB PZA susceptibility test uses radioactive labeled carbon dioxide ("CO2) to monitor organism growth.
• The BACTEC® MGIT™ 960 PZA susceptibility test data are automatically . interpreted by the instrument software while the BACTEC® 460TB PZA susceptibility test data are manually calculated for result interpretation.
• The BACTEC® MGIT™ 960 PZA susceptibility test is performed using . organism suspensions prepared directly from solid or liquid source while the BACTEC® 460TB PZA susceptibility test requires the solid or liquid source isolate to be subcultured into a BACTEC® 460TB 12B medium vial prior to performing the PZA susceptibility test.

2

SUMMARY OF SUBSTANTIAL EQUIVALENCE TESTING DATA:

Analytical Studies:

Reproducibility Testing

Reproducibility of the BACTEC® MGIT™ 960 PZA susceptibility test was evaluated using twenty-six qualified Mycobacterium tuberculosis strains (including three ATCC® strains). Three different lots of the reagents required to conduct the BACTEC® MGIT™ 960 PZA susceptibility test were evaluated. Observed results were compared to the expected results. The overall reproducibility was 96.8%.

CDC Challenge Panel Testing

The performance of the BACTEC® MGIT™ 960 PZA susceptibility test was evaluated using a panel of challenge strains obtained from the Centers for Disease Control and Prevention (CDC). Observed results were compared to the CDC expected results. The percent agreement was 98.7% to the CDC expected results.

Clinical Studies:

The BACTEC® MGIT™ 960 PZA susceptibility test was evaluated at four geographically diverse clinical sites, composed of regional reference centers and university-based laboratories.

Reproducibility Testing

The reproducibility of the BACTEC® MGIT™ 960 PZA Kit was evaluated at the clinical sites using a panel of five qualified strains. Observed results were compared to expected results. Overall reproducibility was 94%, with a range across sites of 86-100%.

CDC Challenge Panel Testing

The performance of the BACTEC® MGIT™ 960 PZA Kit was evaluated using a panel of challenge strains obtained from the Centers for Disease Control and Prevention (CDC). Observed results were compared to the CDC expected results. The percent agreement was 91.7% to the CDC expected results.

3

Clinical Isolate Testing

A total of 118 clinical strains of Mycobacterium tuberculosis were evaluated with the BACTEC® MGIT™ 960 PZA susceptibility test and the BACTEC® 460TB PZA test (reference method). This testing included fresh clinical and subculture isolates from both liquid and solid source cultures. A total of 228 PZA test results were generated and analyzed.

Category agreement was calculated for the isolates tested from both liquid and solid source cultures. The BACTEC® MGIT™ 960 PZA susceptibility test demonstrated a category agreement for liguid source culture of 98.2% and a category agreement of 95.6% for solid source culture.

The overall performance data demonstrate that the BACTEC® MGIT™ 960 PZA THE STORIE ponomianos attact actIACTEC® MGIT™ 960 System, is substantially equivalent to the BACTEC® 460TB PZA susceptibility test (K895362).

1 The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence as found in the Federal Food. Drug and Cosmetic Act, as amended and as applied under 21 CFR 807. Subpart E under which a device can be marketed without premarket approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the U.S. Patent Laws or their application by the courts.

4

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three curved lines representing its wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.

JUL 1 3 2002

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Michelle B. Bandy Regulatory Affairs Specialist BD Diagnostic Systems Becton, Dickinson and Company 7 Loveton Circle Sparks, MD 21152

Re: K021582

Trade/Device Name: BACTEC® MGIT™ 960 PZA Kit Pyrazinamide Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Powder Regulatory Class: Class II Product Code: MJA Dated: May 13, 2002 Received: May 14, 2002

Dear Ms. Bandy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

5

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number [phone]. or [phone] or at its internet address "http://www.fda.gov/cdrb/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

6

Image /page/6/Picture/0 description: The image appears to be a close-up shot of a textured surface. The texture is rough and uneven, with a mix of light and dark areas. The lighting is somewhat diffused, creating soft shadows that accentuate the texture. The overall impression is one of natural or weathered material, possibly stone or a similar substance.

510(k) Number (if known): K021582

Page _1

Device Name: _________________________________________________________________________________________________________________________________________________________________

Indications for Use:

The BACTEC® MGIT™ 960 PZA Kit is a rapid qualitative procedure for susceptibility testing of Mycobacterium tuberculosis, from culture, to pyrazinamide (PZA).

The BACTEC® MGIT™ 960 PZA Kit is used with the BACTEC® MGIT™ 960 System. The BACTEC® MGIT™ 960 PZA Kit final test concentration is 100 µg/mL for pyrazinamide.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Ludoli In. Poole

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K021582

*For Prescription Use

(Optional Format 3-10-98)